[Market Movement Interpretation] Absci Soars on September 17: Conference Engagement + AI Drug Development + ABS-201

1. On September 16, the company participated in the 24th Annual Global Healthcare Conference at Morgan Stanley, holding a fireside chat to continuously showcase its generative AI drug research and development platform and progress in the clinical pipeline.
2. On August 11, the company announced the interim data from the Phase I clinical trial of ABS-201. Results showed good drug tolerability and an estimated half-life of at least 65 days, supporting the potential for two to three doses per half-year in the future.
3. On August 11, the company completed a $100 million underwritten offering, which included a $40 million strategic investment from Eli Lilly; as of June 30, cash, cash equivalents, and marketable securities are expected to support operations through the second half of 2028.

(Disclaimer: This content has been generated by AI technology summarizing public information and is for reference only. It does not constitute investment advice.)